Systemic adverse events following rituximab therapy in patients with Graves' disease

D El Fassi, Claus Henrik Nielsen, Michael Peter Junker, H C Hasselbalch, L Hegedüs

30 Citationer (Scopus)

Abstract

Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.
OriginalsprogEngelsk
TidsskriftJournal of Endocrinological Investigation
Vol/bind34
Udgave nummer7
Sider (fra-til)e163-7
ISSN0391-4097
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Systemic adverse events following rituximab therapy in patients with Graves' disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater